Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01902173
Title Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

Advanced Solid Tumor

melanoma

Therapies

Dabrafenib + Trametinib + Uprosertib

Dabrafenib + Uprosertib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST